Skip to main content
Erschienen in: Journal of Gastroenterology 12/2011

01.12.2011 | Original Article—Liver, Pancreas, and Biliary Tract

Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation

verfasst von: Hiroki Nishikawa, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Azusa Sakamoto, Sinichiro Henmi, Fumihiro Matsuda, Yuji Eso, Tetsuro Ishikawa, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio Osaki

Erschienen in: Journal of Gastroenterology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

In the present study we classified the radicality of percutaneous radiofrequency thermal ablation (RFA) therapy according to the extent of the ablated margin. We measured the local recurrence rate for each radicality grade to evaluate the significance of the grading system in assessing the therapeutic effectiveness of RFA and predicting local tumor progression.

Methods

This retrospective study involved 269 patients with solitary hypervascular hepatocellular carcinoma who had undergone RFA. The mean ± SD observation period after RFA, number of treatment sessions, and tumor diameter were 25.7 ± 19.9 months, 1.2 ± 0.5, and 2.1 ± 0.7 cm, respectively. Patients were evaluated using dynamic computed tomography. We classified the radicality of RFA treatment into four grades (R grades: A, B, C, and D) according to the extent of the ablated tumor margin, calculated the post-RFA cumulative local recurrence rate for each R grade, and analyzed the factors (patient characteristics, biochemical data, contiguous vessels, and tumor marker) contributing to local recurrence.

Results

The cumulative local recurrence rates at 3 years were 6.7, 17.6, 55.8, and 82.2% for Grades A, B, C, and D, respectively. Using univariate analysis, R grade, tumor size (>2 cm), and des-γ-carboxy prothrombin (DCP) (>200 mAU/mL) were shown to be significant factors contributing to local recurrence. However, using multivariate analysis, only the R grade was found to be a significant independent factor.

Conclusions

The proposed R grading method is a valid and useful method for assessing treatment efficacy, and for predicting local tumor progression after RFA.
Literatur
1.
Zurück zum Zitat Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 1996;167:759–68.PubMed Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 1996;167:759–68.PubMed
2.
Zurück zum Zitat Rossi S, Fornari F, Buscarini E, et al. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Interv Radiol. 1993;8:97–103. Rossi S, Fornari F, Buscarini E, et al. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Interv Radiol. 1993;8:97–103.
3.
Zurück zum Zitat Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995;1:73–81.PubMed Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995;1:73–81.PubMed
4.
Zurück zum Zitat Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann Surg. 2000;232:1694–702.CrossRef Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann Surg. 2000;232:1694–702.CrossRef
5.
Zurück zum Zitat Allgaier HP, Deibert P, Zuber I, et al. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999;353:1676–7.PubMedCrossRef Allgaier HP, Deibert P, Zuber I, et al. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999;353:1676–7.PubMedCrossRef
6.
Zurück zum Zitat Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.PubMedCrossRef Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.PubMedCrossRef
7.
Zurück zum Zitat Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73:2259–67.PubMedCrossRef Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73:2259–67.PubMedCrossRef
8.
Zurück zum Zitat Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151–6.PubMedCrossRef Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151–6.PubMedCrossRef
9.
Zurück zum Zitat Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRef Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRef
10.
Zurück zum Zitat Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRef Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRef
11.
Zurück zum Zitat Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115–22.PubMedCrossRef Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115–22.PubMedCrossRef
12.
Zurück zum Zitat Liu CH, Arellano RS, Uppot RN, et al. Radiofrequency ablation of hepatic tumors: effect of post-ablation margin on local tumor progression. Eur Radiol. 2010;20:877–85.PubMedCrossRef Liu CH, Arellano RS, Uppot RN, et al. Radiofrequency ablation of hepatic tumors: effect of post-ablation margin on local tumor progression. Eur Radiol. 2010;20:877–85.PubMedCrossRef
13.
Zurück zum Zitat Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol. 2006;59:432–41.PubMedCrossRef Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol. 2006;59:432–41.PubMedCrossRef
14.
Zurück zum Zitat Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758–65.PubMedCrossRef Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758–65.PubMedCrossRef
15.
Zurück zum Zitat Ikeda K, Kobayashi M, Saitoh S, et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatol Res. 2005;33:241–9.PubMedCrossRef Ikeda K, Kobayashi M, Saitoh S, et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatol Res. 2005;33:241–9.PubMedCrossRef
16.
Zurück zum Zitat Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480–8.PubMedCrossRef Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480–8.PubMedCrossRef
17.
Zurück zum Zitat Tateishi R, Shiina S, Omata M, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.PubMedCrossRef Tateishi R, Shiina S, Omata M, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.PubMedCrossRef
18.
Zurück zum Zitat Takahashi S, Kudo M, Chung H, et al. Initial treatment is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.PubMedCrossRef Takahashi S, Kudo M, Chung H, et al. Initial treatment is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.PubMedCrossRef
19.
Zurück zum Zitat Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007;13:1003–9.PubMed Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007;13:1003–9.PubMed
20.
Zurück zum Zitat Goldberg SN, Grassi CJ, Cardella JF, Society of International Radiology Technology Assessment Committee, International Working Group on Image Guided Tumor Ablation, et al. Image guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728–39.PubMedCrossRef Goldberg SN, Grassi CJ, Cardella JF, Society of International Radiology Technology Assessment Committee, International Working Group on Image Guided Tumor Ablation, et al. Image guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728–39.PubMedCrossRef
21.
Zurück zum Zitat Goldberg SN, Charboneau JW, Dodd GD 3rd, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology. 2003;228:335–45.PubMedCrossRef Goldberg SN, Charboneau JW, Dodd GD 3rd, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology. 2003;228:335–45.PubMedCrossRef
22.
Zurück zum Zitat Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. The Liver Cancer Group of Japan. Hepatology. 2000;32:1224–9.PubMedCrossRef Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. The Liver Cancer Group of Japan. Hepatology. 2000;32:1224–9.PubMedCrossRef
23.
Zurück zum Zitat Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;242:36–42. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;242:36–42.
24.
Zurück zum Zitat Zytoon AA, Ishi H, Murakami K, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol. 2007;37:658–72.PubMedCrossRef Zytoon AA, Ishi H, Murakami K, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol. 2007;37:658–72.PubMedCrossRef
25.
Zurück zum Zitat Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Interv Radiol. 2007;30:696–704.CrossRef Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Interv Radiol. 2007;30:696–704.CrossRef
26.
Zurück zum Zitat Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007;26:1055–63.PubMed Chen MH, Wu W, Yang W, et al. The use of contrast-enhanced ultrasonography in the selection of patients with hepatocellular carcinoma for radio frequency ablation therapy. J Ultrasound Med. 2007;26:1055–63.PubMed
27.
Zurück zum Zitat Osaki Y, Suginosita Y, Kimura T, et al. Usefulness of real-time virtual sonography (RVS) in treatment of hepatocellular carcinoma. Medix. 2005;42:15–20. Osaki Y, Suginosita Y, Kimura T, et al. Usefulness of real-time virtual sonography (RVS) in treatment of hepatocellular carcinoma. Medix. 2005;42:15–20.
28.
Zurück zum Zitat Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115:571–80.PubMedCrossRef Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115:571–80.PubMedCrossRef
29.
Zurück zum Zitat Ikeda K, Kobayashi M, Seko Y, et al. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res. 2010;40:1168–75.PubMedCrossRef Ikeda K, Kobayashi M, Seko Y, et al. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res. 2010;40:1168–75.PubMedCrossRef
30.
Zurück zum Zitat Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–7.PubMedCrossRef Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–7.PubMedCrossRef
Metadaten
Titel
Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation
verfasst von
Hiroki Nishikawa
Tadashi Inuzuka
Haruhiko Takeda
Jun Nakajima
Azusa Sakamoto
Sinichiro Henmi
Fumihiro Matsuda
Yuji Eso
Tetsuro Ishikawa
Sumio Saito
Ryuichi Kita
Toru Kimura
Yukio Osaki
Publikationsdatum
01.12.2011
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 12/2011
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0452-4

Weitere Artikel der Ausgabe 12/2011

Journal of Gastroenterology 12/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.